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Results

Lay Summary
TINU is a rare condition that causes inflammation of
the kidneys (TubuloInterstitial Nephritis) and eyes
(Uveitis). This research study describes 9 children
with TINU. We found that a urine test called beta-2microglobulin
(β2MG) can
detect
kidney
inflammation in some children that might have
otherwise not been recognized with usual clinical
testing. All patients had eye inflammation that was
hard to control. With treatment, all had good vision
but 4 developed mildly decreased kidney function.

Background/Objective
Tubulointerstitial nephritis and uveitis (TINU)
syndrome is an inflammatory disease that affects the
kidneys and eyes. TINU is rare, but likely underrecognized due to variable presentation, nonspecific
symptoms, and lack of universally accepted
diagnostic criteria. The optimal treatment approach
is unknown. This study aimed to contribute further
knowledge about TINU by describing disease
features and treatment response in a single-center
cohort.

Methods
A retrospective chart review was performed of
children diagnosed with TINU at a tertiary care
children’s
hospital
since
January
2013.
Demographics, clinical features, laboratory testing,
eye exam findings and complications, kidney biopsy
results, and treatment response are described.

Table 1. Subject Demographic and Clinical Characteristics
Characteristic
Age at diagnosis (years)
Male
Presenting disease feature
Uveitis (TIN diagnosed during initial workup)
Uveitis (TIN diagnosed during medication taper at month 51)
Tubulointerstitial nephritis (uveitis diagnosed during initial
workup)
Baseline Laboratory Findings
Elevated ESR
Anemia
Elevated serum creatinine
Baseline urinalysis findings
Normal
Trace glucose or trace protein only
More significant abnormalities (proteinuria, hematuria,
and/or glycosuria)
Urine β2MG
Elevated at baseline (normal < 300 mcg/L)*
Mean β2MG
Impaired final estimated glomerular filtration rate (eGFR)
<90mL/min/1.73m2)
Uveitis characteristics
Bilateral
Symptomatic
Isolated anterior uveitis
Anterior uveitis with papillitis (optic nerve edema)
Ocular complications
Synechiae
Cataract
Band keratopathy
Best corrected visual acuity (BCVA) better than 20/40
Baseline
Final

N (%) or mean
(range)
12.4 (8.8-16)
6 (66.7%)
6 (66.7%)
1 (11.1%)
2 (22.2%)
3 (33.3%)
6 (66.7%)
5 (55.5%)
3 (33.3%)
2 (22.2 %)
4 (44.4%)
8 (88.9%)
14,434 (76447,500 mcg/L)
4 (44.4%)
7 (77.8%)
8 (88.9%)
5 (55.5%)
4 (44.4%)

5 (55.5%)
2 (22.2%)
1 (11.1%)
n=18 eyes
14 (77.8%)
18 (100%)

*One patient did not have β2MG checked at presentation- β2MG was later elevated at
time of uveitis flare/AIN diagnosis.

Clinical features are shown in Table 1.
• 100% patients demonstrated uveitis at initial diagnosis.
• 4 patients had normal serum creatinine and 5 had normal or near normal urinalysis; however, urine β2MG was
significantly elevated in all patients at the time of AIN diagnosis.
Treatment response is shown
in Figure 1.
• 100% required at least one
chronic immunomodulator
for uveitis control.
• 8 patients achieved uveitis
quiescence, one was lost
to follow up. 5 had at least
one ocular complication,
but visual outcomes were
good (best corrected visual
acuity 20/40 or better in
100%) at last visit.
• All had improvement in
eGFR, with 5/9 (55.5%)
normal at the last visit.

Figure 1. Uveitis response to steroid-sparing medications

Conclusions
•

•
•

Urine dipstick and serum creatinine alone were inadequate to identify all patients with AIN; however, urine
β2MG may be a more sensitive screening tool for TINU in children with uveitis.
All patients required chronic immunomodulation to achieve steroid-free uveitis control; most required tumornecrosis-factor-α inhibition.
Future multi-center studies are key to furthering understanding of this rare condition and determining optimal
treatment approach.
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